INCIDENCE OF HYPERTENSION IN ASTHMA PATIENTS WHO TREATED WITH BETA-2 AGONISTS BRONCHODILATORS
Objective: To determine the prevalence of hypertension in hospitalized patients with asthma who were treated with beta-2 agonists. To evaluate the correlation between the duration of the use of beta-2 agonist with the incidence of hypertension.
Methods: This research is a descriptive epidemiological, observational cross-sectional and retrospective study design. The study population was all adult asthma patients (age â‰¥ 25) without a concomitant diseases such as hypertension or metabolic syndrome treated with Î²2 agonists as a bronchodilator and underwent hospitalized in January 2015-December 2015 (n=108). Patient data were collected from the medical record. Data were analyzed using univariate and bivariate to count the number of occurrences of hypertension and recognizing the correlation between the duration of the use of Î²2 agonists with hypertension event.
Results: The incidence of hypertension in patients with asthma who were treated with beta-2 agonists are 50, 93% at the stage of pre-hypertension (120 mm Hg/80 mm Hg) and 25, 9% in stage I hypertension (140 mmHg/90 mmHg). Body weight and duration of therapy with a Î²2 agonist positively correlated with the incidence of hypertension with a correlation coefficient (r) 0.231 and 0.386 respectively.
Conclusion: In this study, duration of therapy with a Î²2 agonist in asthma patients positively correlated with the incidence of hypertension.
2. Baky AA. Inflammation in asthma. Egypt J Pediatr Allergy Immunol 2003;1:68â€“70.
3. Epidemiology of Asthma: Prevalence and Burden of Disease: Croisant S. In: Brasier AR. editors. Heterogeneity in asthma, advances in experimental medicine and biology. New York: Springer Science+Business Media; 2014. p. 17-21.
4. Song WJ, Kang MG, Chang YS, Cho SH. Epidemiology of adult asthma in Asia: toward a better understanding. Asian Pac J Allergy Immunol 2014;4:75â€“85.
5. de Nijs SB, Venekamp LN, Bel EH. Adult-onset asthma: Is it really different? Eur Respir Rev 2013;22:44â€“52.
6. GINA. Pocket Guide for asthma management and prevention. Glob Initiat Asthma; 2015. p. 32.
7. Fitzgerald JM, Levy ML. Global strategy for asthma management and prevention (2015 update). Glob Strateg Asthma Manag Prev; 2015.
8. Zdanowicz MM. Teachers topics pharmacotherapy of asthma. Am J Pharm Educ 2007;71:1â€“12.
9. Morris J. Asthma medication. Medscape; 2016. Available from: http://emedicine.medscape.com/article/296301-treatment. [Last accessed on 26 Oct 2016]
10. Barisione G, Baroffio M, Crimi E, Brusasco V. Beta-adrenergic agonists. Pharmaceuticals 2010;3:1016â€“44.
11. Macie C, Wooldrage K, Manfreda J, Anthonisen N. Cardiovascular morbidity and the use of inhaled broncho-dilators. Int J COPD 2008;3:163â€“9.
12. Lemaitre RN, Siscovick DS, Psaty BM, Pearce RM, Raghunathan TE, Whitsel EA, et al. Inhaled beta-2 adrenergic receptor agonists and primary cardiac arrest. Am J Med 2002;113:711â€“6.
13. Bisgaard H, Bonnelykke K. Long-term studies of the natural history of asthma in childhood. J Allergy Clin Immunol 2010;126:187â€“97.
14. Indonesia Health Ministry. Basic health research. Indonesia Research and Health Development agency; 2014. p. 87.
15. Network GA. The global asthma report 2014. Available from: http://www.globalasthmanetwork.org/ [Last accessed on 26 Oct 2016]
16. Humayun A, Shah AS, Sultana R. Relation of hypertension with body mass index and age in a male and female population of Peshawar. Pakistan J Ayub Med Coll Abbottabad 2009;21:63â€“5.
17. Pinto E. Blood pressure and ageing. Postgrad Med J 2007;83:109â€“14.
18. Jaakkola MS, Piipari R, Jaakkola N, Jaakkola JJK. Environmental tobacco smoke and adult-onset asthma: a population-based incident case-control study. Am J Public Health 2003;93:2055â€“60.
19. Nowobilski R, FurgaÅ‚ M, Polczyk R, de Barbaro B, Szczeklik A. Gender gap in psychogenic factors may affect the perception of asthma symptoms. J Investig Allerg Clin Immunol 2011;21:193â€“8.
20. Vayghan HJ, Esfanjani AT, Mameghani ME. Sex differences in serum leptin and adiponectin levels in apparently healthy iranian adults. Int Res J Appl Basic Sci 2013;4:3099â€“103.
21. Khokhar KK, Sidhu S, Kaur G. Correlation between leptin level and hypertension in normal and obese pre-and postmenopausal women. Eur J Endocrinol 2010;163:873â€“8.
22. Macsali F, Svanes C, BjÃ¸rge L, Omenaas ER, Real FG. Respiratory health in women: from menarche to menopause. Expert Rev Respir Med 2012;6:187â€“202.
23. Bellia V, Augugliaro G. Asthma and menopause. Monaldi Arch Chest Dis 2007;67:125â€“7.
24. Troisi RJ, Speizer FE, Willett WC, Trichopoulos D, Rosner B. Menopause, postmenopausal estrogen preparations, and the risk of adult-onset asthmaâ€“a prospective cohort study. Am J Respir Crit Care Med 1995;152:1183â€“8.
25. Shore SA, Johnston RA. Obesity and asthma. Pharmacol Ther 2006;110:83â€“102.
26. Beuther DA, Weiss ST, Sutherland ER. Obesity and asthma. Am J Respir Crit Care Med 2006;174:112â€“9.
27. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AWJr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003;112:1796â€“808.
28. Ingle PV, Patel DM. C-reactive protein in various disease conditionâ€“an overview. Asian J Pharm Clin Res 2011;4:9-13.
29. Barisione G, Baroffio M, Crimi E, Brusasco V. Beta-adrenergic agonists. Pharmaceuticals 2010;3:1016â€“44.
30. Fernandes BL, Henry JP, Goldie GR. Î²-Adrenoceptor agonists. Pharma and Ther of Asthma and COPD. Available from: www.springer.com. [Last accessed on 06 Nov 2016]
31. Kaur M, Holden NS, Wilson SM, Sukkar MB, Chung KF, Barnes PJ, et al. Effect of beta-2 adrenoceptor agonists and other cAMP-elevating agents on inflammatory gene expression in human ASM cells: a role for protein kinase A. Am J Physiol Lung Cell Mol Physiol 2008;295:L505â€“14.
32. Sears MR, Hamilton MB. Adverse effects of Î²-agonists. J Aller Clin Immunol 2002;110:322â€“8.